On a mission to bring single-cell sequencing to cell and gene therapy
Cell & Gene Therapy Insights 2021; 7(1), 111–120
Published: 24 February 2021
Charlie Silver, Mission Bio
CEO and co-founder of Mission Bio, where he leads a team dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics. Charlie has dedicated his career to commercializing next-generation hardware technology and scientific instrumentation at emerging ventures in healthcare and semiconductor industries. Prior to Mission Bio, he led R&D and Product at Novelx (acquired by Agilent) and then served in R&D and Marketing at Agilent. Charlie received a joint MBA from UC Berkeley and Columbia University, an MS in physics from UW Madison, and a BA in physics from Columbia University.